| Literature DB >> 22028953 |
Zaki Noah Hasan1, Mousa Qasim Hussein, Ghazi Farhan Haji.
Abstract
Objective. To assess differences in age of onset, hypertension duration, type of drug, treatment compliance, and salt-free diet compliance between patients with stroke and myocardial infarction. Patients and Methods. The study was conducted in 3 hospitals in Baghdad between June 2010 and June 2011. First group includes 81 stroke patients (36 females and 45 males), age ranges between (33-82 years). Second group includes 110 myocardial infarction patients (46 females and 64 males), ages ranges from (23-76 years). Results. Salt-free diet noncompliance was seen in 69% and 62% of Myocardial infarction and stroke groups, respectively. Silent hypertension was seen in 6.3% and 19.7% of myocardial infarction and stroke groups, respectively. Noncompliant on antihypertensive therapy was seen in 61%, 71%, and 48% of the total, myocardial infarction, and stroke groups, respectively. The drug type was 24% angiotensin converting enzyme inhibitor, 18.8% combined drugs, 16.2% Beta Blocker, 11% angiotensin 11 receptor blocker, 10.4% calcium channel blocker and 7.3% diuretic. In stroke group, the commonest drug was 23% angiotensin converting inhibitor and the least (5%) was angiotensin receptor blocker. In myocardial infarction group, the commonest drug was 25% Angiotensin Converting Inhibitor and the least (8%) was diuretic. Discussion and Conclusion. Silent hypertension was high in Iraq. Salt-free diet noncompliance was high in both groups; drug noncompliance was significantly higher in patients with myocardial infarction. Angiotensin 11 receptor blocker use was associated significantly with myocardial infarction more than in stroke.Entities:
Year: 2011 PMID: 22028953 PMCID: PMC3199046 DOI: 10.4061/2011/701029
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Gender distribution, salt-free diet compliance, and age below 40 years in patients with myocardial infarction and ischemic stroke.
| Myocardial infarction | Ischemic stroke |
| |
|---|---|---|---|
| Gender male | 64/110 (58%) | 45/81 (55.5%) |
|
| Gender female | 46/110 (42%) | 36/81 (44.5%) |
|
| Salt-free diet compliance | 34 110 (31%) | 31/81 (38%) |
|
| Below 40 years | 24/110 (22%) | 6/81 (7%) |
|
Duration of hypertension in both myocardial infarction ischemic stroke groups.
| Not known as hypertensive | Up to 5 years | 6–10 | 11–15 | More than 16 | Total | |
|---|---|---|---|---|---|---|
| Myocardial infarction | 7 (6%) | 3 (2.7%) | 57 (52%) | 34 (31%) | 9 (8%) | 110 |
| Ischemic stroke | 16 (20%) | 2 (2.4%) | 41 (50.6%) | 19 (23.4%) | 3 (3.7%) | 81 |
| Total | 23 (12%) | 5 (2.6%) | 98 (51%) | 53 (27.7%) | 12 (6.2%) | 191 |
|
| Less than 0.0009 | 0.3 | 0.2 | 0.4 | 0.2 |
Treatment compliance and no treatments in both groups of myocardial infarction and ischemic stroke.
| No treatment | Not compliant | Compliant | Total | |
|---|---|---|---|---|
| Myocardial infarction | 7 (6%) | 78 (71%) | 25 (22%) | 110 |
| Ischemic stroke | 16 (19.7%) | 39 (48%) | 26 (32.3%) | 81 |
| Total | 23 (12%) | 117 (61%) | 51 (27%) | 191 |
|
|
|
|
|
Treatment drugs type in both groups of Myocardial infarction and stroke.
| Angiotensin receptor blocker | Angiotensin converting inhibitor | Beta blocker | Diuretics | CA channel blocker | Combined | No. of treatment | Total | |
|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | 17/110 | 27/110 | 19/110 | 9/110 | 12/110 | 19/110 | 7/110 | 110 |
| Ischemic stroke | 4/81 | 19/81 | 12/81 | 5/81 | 8/81 | 17/81 | 16/81 | 81 |
| Total | 21/191 | 46/191 | 31/191 | 14/191 | 20/191 | 36/191 | 23/191 | 191 |
| (odds ratio) | (0.990) | (1.146) | (1.17) | (1.247) | (0.54) | (1.301) | (1.653) |